Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 1.736
5-Year Impact Factor – 2.135
Index Copernicus  – 168.52
MEiN – 70 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2013, vol. 22, nr 1, January-February, p. 69–76

Publication type: original article

Language: English

Dietary Determinants of Oxidized-Low-Density Lipoprotein Antibodies in a Sample of Pharmacologically Untreated Non-Smoker Subjects: Data from the Brisighella Heart Study

Dietetyczne wyznaczniki przeciwciał utlenionych lipoprotein małej gęstości w próbce nieleczonych farmakologicznie osób niepalących – dane z badania Brisighella Heart Study

Arrigo F.G. Cicero1,B,C,D,E,F, Alessandra Reggi1,B,D,F, Elisa Tartagni1,B,D,F, Elisa Grandi1,B,D,F, Sergio D’Addato1,B,D,E,F, Claudio Borghi1,A,D,E,F, on behalf of the Brisighella Heart Study Grou1,P

1 Medical and Surgical Sciences Dept., Sant’Orsola-Malpighi University Hospital, Bologna Italy

Abstract

Background. Oxidation makes LDL an immunogenic substrate, stimulating the production of specific autoantibodies against oxidized LDL (ox-LDL Ab). The demonstration of ox-LDL Ab presence in serum indicates the existence of a long-term lipid peroxidation in vivo.
Objectives. The aim of the study is to evaluate the influence of a large number of dietary variables on the dosage of ox-LDL Ab in pharmacologically untreated healthy subjects.
Material and Methods. The Brisighella Heart Study (BHS) is a prospective, population-based longitudinal epidemiological investigation involving 2939 randomly selected adult subjects, resident in the northern Italian rural town of Brisighella. For this study, we analyzed the dietary, clinical and laboratory data of 265 (M: 101, W: 164) pharmacologically untreated non-smoker subjects, evaluating the factors potentially affecting their ox-LDL Ab dosage.
Results. In a multivariate analysis, including age, BMI, hemodynamic and laboratory parameters, the only significant predictor of log-ox-LDL Ab level was age (HR –0.19; 95%CI –0.115 – –0.104, p = 0.001; adjusted R2 = 0.581). Including in the analysis the considered nutritional variables, the best model predicting the log-ox-LDL Ab level included age (HR –0.11; 95%CI –0.116 – –0.105, p < 0.001), the percentage of kcal derived from lipids (HR –0.12; 95%CI –0.134 – –0.112, p < 0.001), copper (OR 0.77; 95%CI 0.475 – 1.076, p < 0.001) and zinc (HR –0.22; 95%CI –0.282 – –0.163, p < 0.001; adjusted R2 = 0.358).
Conclusion. In this population sample of healthy subjects, the main considered dietary components do not influence the ox-LDL Ab level in a clinically relevant manner.

Streszczenie

Wprowadzenie.Utlenianie sprawia, że LDL staje się immunogennym substratem, stymulując wydzielanie określonych autoprzeciwciał przeciwko utlenionym LDL (ox-LDL Ab). Pokazanie obecności ox-LDL Ab w surowicy krwi oznacza istnienie długotrwałej peroksydacji lipidów w warunkach in vivo.
Cel pracy. Ocena wpływu wielu zmiennych związanych z dietą na wydzielanie ox-LDL-Ab u farmakologicznie nieleczonych zdrowych osób.
Materiał i metody. Brisighella Heart Study (BHS) to prospektywne, populacyjne podłużne epidemiologiczne badanie obejmujące 2939 losowo wybranych dorosłych pacjentów, zamieszkujących w małej miejscowości Brisighella na północy Włoch. W tym badaniu autorzy analizowali dietę, dane kliniczne i laboratoryjne 265 (M: 101, K: 164) nieleczonych farmakologicznie niepalących osób, aby ocenić czynniki potencjalnie wpływające na wydzielanie oxLDL-Ab.
Wyniki. Wg analizy wieloczynnikowej, w tym wieku, BMI i parametrów hemodynamicznych i laboratoryjnych, jedynym znaczącym predyktorem log-ox-LDL Ab był wiek (HR –0,19, 95% CI: –0,115 – 0,104, p = 0,001; dostosowane R2 = 0,581). Biorąc pod uwagę zmienne związane z odżywianiem, najlepszym modelem przewidującym log-ox-LDL Ab był wiek (HR –0,11, 95% CI: –0,116 – 0,105, p < 0,001), odsetek kcal pochodzących z lipidów (HR –0,12, 95% CI: –0,134 –0,112, p < 0,001), miedź (OR 0,77, 95% CI 0,475 – 1,076, p < 0,001) i cynk (HR –0,22, 95% CI: –0,282 – 0,163, p < 0,001) (R2 = 0,358 dostosowane).
Wnioski. W badanej próbie populacji osób zdrowych główne wzięte pod uwagę składniki diety nie miały wpływu na stężenie ox-LDL Ab w sposób istotny klinicznie.

Key words

ox-LDL Ab, dietary habit, nutritional determinants, epidemiology.

Słowa kluczowe

ox-LDL-Ab, nawyki dietetyczne, dietetyczne wyznaczniki, epidemiologia.

References (29)

  1. Mitra S, Goyal T, Mehta JL: Oxidized LDL, LOX-1 and atherosclerosis. Cardiovasc Drugs Ther 2011, 25(5), 419– 429.
  2. Hansson GK, Hermansson A: The immune system in atherosclerosis. Nat Immunol 2011, 12(3), 204–212.
  3. Steinerová A, Racek J, Stozický F, Zima T, Fialová L, Lapin A: Antibodies against oxidized LDL – theory and clinical use. Physiol Res 2001, 50(2), 131–141.
  4. Oranje WA, Wolffenbuttel BHR: Lipid peroxidation and atherosclerosis in type II diabetes. J Lab Clin Med 1999, 134, 19–32.
  5. Cojocaru IM, Cojocaru M, Burcin C: IgG-autoantibodies against oxidized low-density lipoprotein in ischemic stroke onset. Rom J Intern Med 2006, 44(2), 165–170.
  6. Rouhl RP, van Oostenbrugge RJ, Theunissen RO, Knottnerus IL, Staals J, Henskens LH, Kroon AA, de Leeuw PW, Lodder J, Tervaert JW, Damoiseaux JG: Autoantibodies against oxidized low-density lipoprotein in cerebral small vessel disease. Stroke 2010, 41(11), 2687–2689.
  7. Swets BP, Brouwer DA, Tervaert JW: Patients with systemic vasculitis have increased levels of autoantibodies against oxidized LDL. Clin Exp Immunol 2001, 124(1), 163–167.
  8. Laczik R, Szodoray P, Veres K, Szomják E, Csípo I, Sipka S Jr, Shoenfeld Y, Szekanecz Z, Soltész P: Assessment of IgG antibodies to oxidized LDL in patients with acute coronary syndrome. Lupus 2011, 20(7), 730–735.
  9. Che J, Li G, Wang W, Li Q, Liu H, Chen K, Liu T: Serum autoantibodies against human oxidized low-density lipoproteins are inversely associated with severity of coronary stenotic lesions calculated by Gensini score. Cardiol J 2011, 18(4), 364–370.
  10. Nicoletti A, Kaveri S, Caligiuri G, Bariety J, Hansson GK: Immunoglobulin treatment reduces atherosclerosis in apo E knockout mice. J Clin Invest 1998, 102, 910–918.
  11. Schiopu A, Frendeus B, Jansson B, Söderberg I, Ljungcrantz I, Araya Z, Shah PK, Carlsson R, Nilsson J, Fredrikson GN: Recombinant antibodies to an oxidized low-density lipoprotein epitope induce rapid regression of atherosclerosis in apobec-1(–/–)/low-density lipoprotein receptor(–/–) mice. J Am Coll Cardiol 2007, 50, 2313–2318.
  12. Liu CS, Lii CK, Ou CC, Tsai CH, Wei YH, Chen HW: Autoantibody against oxidized low-density lipoproteins may be enhanced by cigarette smoking. Chem Biol Inter 2000, 127 (2), 125–137.
  13. Schulpis KH, Tsakiris S, Karikas GA, Moukas M, Behrakis P: Effect of diet on plasma total antioxidant status in phenylketonuric patients. Eur J Clin Nutr 2003, 57 (2), 383–387.
  14. Descovich GC, Cavallo G, Mannino G, Lenzi S: The Brisighella survey: a study of dietary habits. Minerva Med 1983, 74(11), 547–555.
  15. Ardigò D, Bernini F, Borghi C et al. on behalf of the ADSL project investigators: Advanced diagnostic support in lipidology project: role for phenotypic and functional evaluation of lipoproteins in dyslipidemias. Clin Lipidol 2010, 5(3), 329–337.
  16. Cicero AFG, Dormi A, D’Addato S, Borghi C on behalf of the Brisighella Heart Study Staff: From risk factor assessment to cardiovascular disease risk and mortality modification: the first 40 years of the Brisighella Heart Study. Clin Lipidol 2011, 6(3), 269–276.
  17. Gaddi A, Cicero AF, Wani FO, Dormi A, Pasquarelli V, D’Addato S: The realization of a project aimed at reducing the plasmatic lipid level in a large Italian population improves the mean calcium daily intake: the Brisighella Study. Eur J Clin Nutr 2001, 55(2), 97–106.
  18. Tatzber F, Esterbauer H: Autoantibodies to oxidized low density lipoprotein. In: Free Radicals, Lipoprotein Oxidation and Atherosclerosis. Eds.: Bellomo G, Finardi G, Maggi E, Rice-Evance C. London, UK: Richelieu Press: 1995, 245–262.
  19. Castańer O, Fitó M, López-Sabater MC et al. EUROLIVE Study Group: The effect of olive oil polyphenols on antibodies against oxidized LDL. A randomized clinical trial. Clin Nutr 2011, 30(4), 490–493.
  20. Miller AA, De Silva TM, Jackman KA, Sobey CG: Effect of gender and sex hormones on vascular oxidative stress. Clin Exp Pharmacol Physiol 2007, 34(10),1037–1043.
  21. Nabulsi AA, Folsom AR, White A, Patsch W, Heiss G, Wu KK, Szklo M: Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. The Atherosclerosis Risk in Communities Study Investigators. N Engl J Med 1993, 328, 1069–1075.
  22. Frezza M, Di Padova C, Pozzato G, Terpin M, Baraona E, Lieber CS: High blood alcohol levels in women. The role of decreased gastric alcohol dehydrogenase activity and first pass metabolism. N Engl J Med 1990, 322, 95–99.
  23. Di Bari M, Zacchei S, Kritchevsky SB, Kritchevsky SB, Anichini M, Cesaretti S, Chiarlone M, Masotti G, Marchionni N: Anti-oxidized LDL antibodies and wine consumption: a population-based epidemiological study in Dicomano, Italy. Ann Epidemiol 2003, 13(3), 189–195.
  24. Wen Y, Killalea S, Norris LA, Cooke T, Feely J: Vitamin E supplementation in hyperlipidaemic patients: effect of increasing doses on in vitro and in vivo low-density lipoprotein oxidation. Eur J Clin Invest 1999, 29(12), 1027–1034.
  25. Chasapis CT, Loutsidou AC, Spiliopoulou CA, Stefanidou ME: Zinc and human health: an update. Arch Toxicol 2012, 86(4), 521–534.
  26. Yang YJ, Choi BY, Chun BY, Kweon SS, Lee YH, Park PS, Kim MK: Dietary zinc intake is inversely related to subclinical atherosclerosis measured by carotid intima-media thickness. Br J Nutr 2010, 104(8), 1202–1211.
  27. Islamoglu Y, Evliyaoglu O, Tekbas E, Cil H, Elbey MA, Atilgan Z, Kaya H, Bilik Z, Akyuz A, Alan S: The relationship between serum levels of Zn and Cu and severity of coronary atherosclerosis. Biol Trace Elem Res 2011, 144(1–3), 436–444.
  28. Ghayour-Mobarhan M, Taylor A, Kazemi-Bajestani SM, Lanham-New S, Lamb DJ, Vaidya N, Livingstone C, Wang T, Ferns GA: Serum zinc and copper status in dyslipidaemic patients with and without established coronary artery disease. Clin Lab 2008, 54(9–10), 321–329.
  29. de Oliveira Otto MC, Alonso A, Lee DH, Delclos GL, Bertoni AG, Jiang R, Lima JA, Symanski E, Jacobs DR Jr, Nettleton JA: Dietary intakes of zinc and heme iron from red meat, but not from other sources, are associated with greater risk of metabolic syndrome and cardiovascular disease. Am J Nutr 2012, 142(3), 526–533.
© Wroclaw Medical University